First approved in 1997, Rituximab (Rituxan) was the first monoclonal antibody for cancer. It targets CD20 on B-cells, killing lymphoma cells while sparing healthy tissue. The rituximab market report by MRFR shows that non-Hodgkin lymphoma (NHL) is the largest indication, but chronic lymphocytic leukemia (CLL) is the fastest‑growing. The market is $34.52 billion and will hit $52.37 billion by 2035, growing at 3.86% CAGR — steady, not explosive, because biosimilars are eroding prices.

What's driving growth? Intravenous infusion is the largest route of administration, but subcutaneous injection is the fastest‑growing — it takes 5‑7 minutes instead of hours. The rituximab market analysis highlights that hospitals are the largest end‑user segment, but specialty clinics are growing fast — as cancer care shifts to outpatient settings.

What's new? Biosimilars (Riabni, Ruxience) are now widely available, cutting prices by 30‑50%. That's good for patients and healthcare systems, but bad for originator sales. Also, new combination therapies (Rituximab + lenalidomide) are expanding its use in indolent lymphomas.

The bottom line: Rituximab is a mature drug, but it's not obsolete. With biosimilars, more patients can access it. And with subcutaneous formulations, treatment is more convenient. It remains a backbone of B‑cell malignancy therapy.